Moderna, Inc. (NASDAQ:MRNA) Shares Acquired by Metis Global Partners LLC

Metis Global Partners LLC increased its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 13.9% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 14,834 shares of the company’s stock after acquiring an additional 1,814 shares during the period. Metis Global Partners LLC’s holdings in Moderna were worth $991,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of MRNA. Ashton Thomas Private Wealth LLC purchased a new position in shares of Moderna in the second quarter valued at $26,000. Family Firm Inc. purchased a new position in Moderna during the 2nd quarter valued at about $33,000. Bank & Trust Co acquired a new position in Moderna during the second quarter worth about $36,000. Hanseatic Management Services Inc. purchased a new stake in shares of Moderna in the second quarter valued at about $48,000. Finally, Plato Investment Management Ltd grew its position in shares of Moderna by 230.4% in the second quarter. Plato Investment Management Ltd now owns 413 shares of the company’s stock valued at $49,000 after purchasing an additional 288 shares during the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on MRNA shares. Oppenheimer lowered Moderna from an “outperform” rating to a “market perform” rating in a research note on Friday, September 13th. The Goldman Sachs Group decreased their price objective on Moderna from $178.00 to $139.00 and set a “buy” rating on the stock in a research note on Monday, September 16th. Hsbc Global Res raised shares of Moderna from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 28th. Jefferies Financial Group decreased their price target on shares of Moderna from $65.00 to $55.00 and set a “hold” rating on the stock in a research note on Tuesday, October 15th. Finally, UBS Group cut their price objective on shares of Moderna from $140.00 to $108.00 and set a “buy” rating for the company in a research report on Thursday, October 24th. Three equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Moderna has an average rating of “Hold” and a consensus price target of $90.22.

Insider Activity

In related news, CFO James M. Mock sold 715 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the transaction, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. The trade was a 7.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In the last 90 days, insiders have sold 2,930 shares of company stock valued at $217,170. Company insiders own 15.70% of the company’s stock.

Moderna Price Performance

MRNA stock opened at $36.85 on Monday. The stock has a 50-day moving average price of $58.56 and a two-hundred day moving average price of $96.78. The company has a market cap of $14.18 billion, a PE ratio of -6.33 and a beta of 1.69. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. Moderna, Inc. has a 12-month low of $35.80 and a 12-month high of $170.47.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. The firm had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The company’s revenue was up 3.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.39) EPS. As a group, research analysts predict that Moderna, Inc. will post -9.43 EPS for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.